QCG
TVTX icon

Quadrant Capital Group’s Travere Therapeutics TVTX Stock Holding History

Quadrant Capital Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Sell
5,367
-883
-14% -$26.4K ﹤0.01% 1337
2025
Q4 		$239K Sell
6,250
-372
-6% -$12.1K 0.01% 1240
2025
Q3 		$158K Buy
+6,622
New +$124K 0.01% 1337
2025
Q2 		– Sell
-6,724
Closed -$120K – 2536
2025
Q1 		$120K Buy
6,724
+102
+2% +$2.07K ﹤0.01% 1483
2024
Q4 		$115K Hold
6,622
– – 0.01% 985
2024
Q3 		$92.6K Hold
6,622
– – 0.01% 1111
2024
Q2 		$54.4K Buy
6,622
+4,554
+220% +$30.7K ﹤0.01% 1362
2024
Q1 		$15.9K Sell
2,068
-391
-16% -$3.3K ﹤0.01% 1937
2023
Q4 		$22.1K Buy
2,459
+2,419
+6,048% +$17.6K ﹤0.01% 1772
2023
Q3 		$358 Buy
+40
New +$564 ﹤0.01% 2618
2023
Q2 		– Sell
-41
Closed -$923 – 2777
2023
Q1 		$923 Buy
+41
New +$872 ﹤0.01% 2547
2021
Q4 		– Sell
-41
Closed -$1K – 2699
2021
Q3 		$1K Buy
+41
New +$753 ﹤0.01% 2399

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quadrant Capital Group's TVTX Position: Q1 2026 in Review

Quadrant Capital Group reduced its Travere Therapeutics (TVTX) stake by 14% in Q1 2026, selling an estimated $26.4K and leaving 5,367 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

Quadrant Capital Group first reported a position in TVTX in Q3 2021 and has held it in 12 quarters since. The position peaked at $239K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Quadrant Capital Group held 5,367 shares of Travere Therapeutics worth $159K as of Q1 2026.
  • Quadrant Capital Group sold 883 Travere Therapeutics shares in Q1 2026, an estimated $26.4K.
  • Travere Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1337 holding.
  • Quadrant Capital Group first reported a position in Travere Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Quadrant Capital Group's Travere Therapeutics position peaked at $239K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.